Drug Profile

Research programme: small molecule therapeutics - BioVersys

Alternative Names: Anti-virulence program - BioVersys; BV-200

Latest Information Update: 24 Apr 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator BioVersys
Class Anti-infectives; Anti-inflammatories; Skin disorder therapies; Small molecules
Mechanism of Action Transcription factor inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes - Staphylococcal infections

24 Apr 2024 Preclinical trials in Atopic dermatitis in Switzerland (unspecified route) (BioVersys pipeline, April 2024)
28 Nov 2023 No recent reports of development identified for research development in Nosocomial-infections in Switzerland
23 Sep 2021 Early research in Atopic dermatitis in Switzerland (unspecified route) before September 2021 (BioVersys pipeline, September 2021)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com